Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.48 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8075068 | 0.85 | NOTUM (0.54) | TTRSTK39MRGPRX4RAF1SCN9A | |
| SCHEMBL8059420 | 0.83 | PLA2G7 (0.45) | TTRLPAR1LPAR5SRD5A2MRGPRX4 | |
| SCHEMBL8068494 | 0.82 | PLA2G7 (0.46) | TTRLPAR1LPAR5SRD5A2EGLN1 | |
| SCHEMBL9788489 | 0.82 | MRGPRX4 (0.61) | TTRAKR1C3LPAR1LPAR5MRGPRX4 | |
| SCHEMBL10670283 | 0.81 | RXRA (0.54) | AKR1C3SRD5A2MRGPRX4RXRARXRB | |
| SCHEMBL16319437 | 0.81 | KMO (0.56) | TTREGLN1MRGPRX4RXRARXRB | |
| Hydrochloric Acid SCHEMBL8503964 | 0.81 | SLC9A1 (0.49) | — | |
| SCHEMBL8068456 | 0.80 | TTR (0.44) | TTRLPAR1LPAR5SRD5A2MRGPRX4 | |
| SCHEMBL30835355 | 0.80 | RXRA (0.46) | TTRMRGPRX4RXRARXRBRXRG | |
| SCHEMBL11462504 | 0.80 | TTR (0.81) | TTRAKR1C3SRD5A2MRGPRX4NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868055-B | Inhibitors of TRPC6 | 勃林格殷格翰国际有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11370771-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| US-11370771-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| US-20210053935-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-20210053935-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| EP-3752503-A1 | INHIBITORS OF TRPC6 | Boehringer Ingelheim International GmbH (DE) | 2020-12-23 | — | — | EP | disclosed |
| CN-111868055-A | Inhibitors of TRPC6 | 勃林格殷格翰国际有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019161010-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019161010-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-6057322-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
| EP-0723956-B1 | Basically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics as well as medicaments containing them | HOECHST AG (DE) | 1999-10-13 | — | — | EP | disclosed |
| EP-0723956-A1 | Basically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics as well as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053935-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | TTR 1641/4885AKR1C3 361/4885LPAR1 284/4885 |
| US-11370771-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | TTR 1641/4885AKR1C3 361/4885LPAR1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.